Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy
In its latest earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs.
Previous Post
NaV1.8 Pain Signal Inhibitor VX-993 Fails to Show Efficacy in Phase 2 Trial of Acute Pain
Next Post
STAT+: Eli Lilly’s much-anticipated obesity pill yields modest results
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago